Tumor response assessments with diffusion and perfusion MRI

Journal of Magnetic Resonance Imaging

Volumn 35, Issue 4, 2012, Pages 745-763

  Li, Sonia P ^a   Padhani, Anwar R ^b  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

diffusion weighted MRI; dynamic contrast enhanced MRI; response biomarkers

Indexed keywords

BEVACIZUMAB; CEDIRANIB; COMBRETASTATIN A4 PHOSPHATE; CONTRAST MEDIUM; SORAFENIB; TAXANE DERIVATIVE; VASCULOTROPIN;

ANGIOGENESIS; ANISOTROPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTIFICIAL EMBOLISM; BLOOD VESSEL PERMEABILITY; BONE MARROW; BONE MARROW DISEASE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CELL ORGANELLE; CHEMORADIOTHERAPY; COLORECTAL CANCER; CONTRAST ENHANCEMENT; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; ECHO PLANAR IMAGING; ELECTRON SPIN RESONANCE; GLEASON SCORE; GLIOMA; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; METASTASIS; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; OUTCOME ASSESSMENT; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RADIOFREQUENCY ABLATION; REVIEW; RHABDOMYOSARCOMA; SIGNAL NOISE RATIO; SOFT TISSUE SARCOMA; TECHNOLOGY; TISSUE PERFUSION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME; VALIDATION PROCESS;

ANIMALS; DIFFUSION MAGNETIC RESONANCE IMAGING; FORECASTING; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); TREATMENT OUTCOME;

EID: 84863338516     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22838     Document Type: Review

References (120)

1. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
2. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28: 1963-1972.
3. Husband JE, Schwartz LH, Spencer J, et al. Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society. Br J Cancer 2004; 90: 2256-2260.
4. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007; 25: 1760-1764.
5. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
6. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
7. Padhani AR, Miles KA,. Multiparametric imaging of tumor response to therapy. Radiology 2010; 256: 348-364.
8. Koh DM, Collins DJ,. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007; 188: 1622-1635.
9. Patterson DM, Padhani AR, Collins DJ,. Technology insight: water diffusion MRI-a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol 2008; 5: 220-223.
10. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11: 102-125.
11. Le Bihan D,. Principles of diffusion MR Imaging and spectroscopy. In:, Le Bihan D, editor. Diffusion and perfusion magnetic resonance imaging: applications to functional MRI, 1st ed. New York: Raven Press; 1995.
12. Koh DM, Padhani AR,. Diffusion-weighted MRI: a new functional clinical technique for tumour imaging. Br J Radiol 2006; 79: 633-635.
13. Thoeny HC, De Keyzer F,. Extracranial applications of diffusion-weighted magnetic resonance imaging. Eur Radiol 2007; 17: 1385-1393.
14. Thoeny HC, De Keyzer F, Boesch C, Hermans R,. Diffusion-weighted imaging of the parotid gland: Influence of the choice of b-values on the apparent diffusion coefficient value. J Magn Reson Imaging 2004; 20: 786-790.
15. Padhani AR, Koh DM,. Diffusion MR imaging for monitoring of treatment response. Magn Reson Imaging Clin N Am 2011; 19: 181-209.
16. Manenti G, Di Roma M, Mancino S, et al. Malignant renal neoplasms: correlation between ADC values and cellularity in diffusion weighted magnetic resonance imaging at 3 T. Radiol Med (Torino) 2008; 113: 199-213.
17. Humphries PD, Sebire NJ, Siegel MJ, Olsen OE,. Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity. Radiology 2007; 245: 848-854.
18. Zelhof B, Pickles M, Liney G, et al. Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int 2009; 103: 883-888.
19. Ellingson BM, Malkin MG, Rand SD, et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging 2010; 31: 538-548.
20. Hillengass J, Bauerle T, Bartl R, et al. Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology. Br J Haematol 2011; 153: 721-728.
21. Nonomura Y, Yasumoto M, Yoshimura R, et al. Relationship between bone marrow cellularity and apparent diffusion coefficient. J Magn Reson Imaging 2001; 13: 757-760.
22. Messiou C, deSouza NM,. Diffusion weighted magnetic resonance imaging of metastatic bone disease: a biomarker for treatment response monitoring. Cancer Biomark 2010; 6: 21-32.
23. Wang XZ, Wang B, Gao ZQ, et al. Diffusion-weighted imaging of prostate cancer: correlation between apparent diffusion coefficient values and tumor proliferation. J Magn Reson Imaging 2009; 29: 1360-1366.
24. Woodfield CA, Tung GA, Grand DJ, Pezzullo JA, Machan JT, Renzulli JF 2nd,. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR Am J Roentgenol 2010; 194: W316-322.
25. Lyng H, Haraldseth O, Rofstad EK,. Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med 2000; 43: 828-836.
26. Liimatainen T, Hakumaki JM, Kauppinen RA, Ala-Korpela M,. Monitoring of gliomas in vivo by diffusion MRI and (1)H MRS during gene therapy-induced apoptosis: interrelationships between water diffusion and mobile lipids. NMR Biomed 2009; 22: 272-279.
27. Nakajo M, Kajiya Y, Kaneko T, et al. FDG PET/CT and diffusion-weighted imaging for breast cancer: prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion. Eur J Nucl Med Mol Imaging 2010; 37: 2011-2020.
28. Turkbey B, Shah VP, Pang Y, et al. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology 2011; 258: 488-495.
29. Lemaire L, Howe FA, Rodrigues LM,. Assessment of induced rat mammary tumour response to chemotherapy using the apparent diffusion coefficient of tissue water as determined by diffusion-weighted 1H-NMR spectroscopy in vivo. Magma 1999; 8: 20-26.
30. Dzik-Jurasz A, Domenig C, George M, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002; 360: 307-308.
31. DeVries AF, Kremser C, Hein PA, et al. Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys 2003; 56: 958-965.
32. Cui Y, Zhang XP, Sun YS, Tang L, Shen L,. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008; 248: 894-900.
33. Swinson DE, Jones JL, Richardson D, Cox G, Edwards JG, O'Byrne KJ,. Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. Lung Cancer 2002; 37: 235-240.
34. Roth Y, Tichler T, Kostenich G, et al. High-b-value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice. Radiology 2004; 232: 685-692.
35. Sun YS, Zhang XP, Tang L, et al. Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging. Radiology 2010; 254: 170-178.
36. Koh DM, Scurr E, Collins D, et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol 2007; 188: 1001-1008.
37. Park SH, Moon WK, Cho N, et al. Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology 2010; 257: 56-63.
38. Thoeny HC, De Keyzer F, Vandecaveye V, et al. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology 2005; 237: 492-499.
39. Koh DM, Blackledge M, Collins DJ, et al. Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 2009; 19: 2728-2738.
40. Hamstra DA, Rehemtulla A, Ross BD,. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 2007; 25: 4104-4109.
41. Thoeny HC, Ross BD,. Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 2010; 32: 2-16.
42. Theilmann RJ, Borders R, Trouard TP, et al. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 2004; 6: 831-837.
43. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF,. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 2009; 250: 466-473.
44. Uhl M, Saueressig U, van Buiren, et al. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Invest Radiol 2006; 41: 618-623.
45. Hamstra DA, Galban CJ, Meyer CR, et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 2008; 26: 3387-3394.
46. Oka K, Yakushiji T, Sato H, Hirai T, Yamashita Y, Mizuta H,. The value of diffusion-weighted imaging for monitoring the chemotherapeutic response of osteosarcoma: a comparison between average apparent diffusion coefficient and minimum apparent diffusion coefficient. Skeletal Radiol 2010; 39: 141-146.
47. Dudeck O, Zeile M, Pink D, et al. Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J Magn Reson Imaging 2008; 27: 1109-1113.
48. Jordan BF, Runquist M, Raghunand N, et al. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia 2005; 7: 475-485.
49. Pickles MD, Gibbs P, Lowry M,. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 2006; 24: 843-847.
50. Sharma U, Danishad KK, Seenu V, Jagannathan NR,. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed 2009; 22: 104-113.
51. Lee SC, Poptani H, Pickup S, et al. Early detection of radiation therapy response in non-Hodgkin's lymphoma xenografts by in vivo 1H magnetic resonance spectroscopy and imaging. NMR Biomed 2010; 23: 624-632.
52. Hamstra DA, Lee KC, Moffat BA, Chenevert TL, Rehemtulla A, Ross BD,. Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck. Transl Oncol 2008; 1: 187-194.
53. Larocque MP, Syme A, Yahya A, Wachowicz K, Allalunis-Turner J, Fallone BG,. Monitoring T2 and ADC at 9.4 T following fractionated external beam radiation therapy in a mouse model. Phys Med Biol 2010; 55: 1381-1393.
54. Galban CJ, Mukherji SK, Chenevert TL, et al. A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol 2009; 2: 184-190.
55. Hamstra DA, Chenevert TL, Moffat BA, et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A 2005; 102: 16759-16764.
56. Liu Y, Bai R, Sun H, Liu H, Zhao X, Li Y,. Diffusion-weighted imaging in predicting and monitoring the response of uterine cervical cancer to combined chemoradiation. Clin Radiol 2009; 64: 1067-1074.
57. Jain R, Scarpace LM, Ellika S, et al. Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. J Neurooncol 2010; 96: 423-431.
58. Batchelor TT, Duda DG, di Tomaso E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010; 28: 2817-2823.
59. Schraml C, Schwenzer NF, Martirosian P, et al. Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol 2009; 193: W301-307.
60. Thoeny HC, De Keyzer F, Chen F, et al. Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration. Neoplasia 2005; 7: 779-787.
61. d'Arcy JA, Collins DJ, Padhani AR, Walker-Samuel S, Suckling J, Leach MO,. Informatics in radiology (infoRAD): magnetic resonance imaging workbench: analysis and visualization of dynamic contrast-enhanced MR imaging data. Radiographics 2006; 26: 621-632.
62. Zweifel M, Padhani AR,. Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools? Eur J Nucl Med Mol Imaging 2010; 37 (Suppl 1): S164-182.
63. Fritz-Hansen T, Rostrup E, Larsson HB, Sondergaard L, Ring P, Henriksen O,. Measurement of the arterial concentration of Gd-DTPA using MRI: a step toward quantitative perfusion imaging. Magn Reson Med 1996; 36: 225-231.
64. Walker-Samuel S, Parker CC, Leach MO, Collins DJ,. Reproducibility of reference tissue quantification of dynamic contrast-enhanced data: comparison with a fixed vascular input function. Phys Med Biol 2007; 52: 75-89.
65. Walker-Samuel S, Leach MO, Collins DJ,. Evaluation of response to treatment using DCE-MRI: the relationship between initial area under the gadolinium curve (IAUGC) and quantitative pharmacokinetic analysis. Phys Med Biol 2006; 51: 3593-3602.
66. O'Connor JP, Jackson A, Parker GJ, Jayson GC,. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007; 96: 189-195.
67. Padhani AR,. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 2002; 16: 407-422.
68. Collins DJ, Padhani AR,. Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges. IEEE Eng Med Biol Mag 2004; 23: 65-83.
69. Kety S,. Measurement of local blood flow by the exchange of an inert, diffusible substance. Methods Med Res 1960; 8: 228-236.
70. Kety S,. Blood-tissue exchange methods. Theory of blood-tissue exchange and its application to measurement of blood flow. Methods Med Res 1960; 8: 223-227.
71. Tofts P, Brix G, Buckley D, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10: 223-232.
72. Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005; 92: 1599-1610.
73. Jackson A, O'Connor JP, Parker GJ, Jayson GC,. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 2007; 13: 3449-3459.
74. Mullamitha SA, Ton NC, Parker GJ, et al. Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res 2007; 13: 2128-2135.
75. Mitchell CL, O'Connor JP, Jackson A, et al. Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy. Ann Oncol 2010; 21: 1982-1989.
76. Taylor NJ, Tunariu N, Stirling JJ, et al. Non-enhancing pixels: a specific additional DCE-MRI kinetic parameter for assessing antivascular effects of anti-angiogenic and vascular disruptive agents. In: Proc 17th Annual Meeting ISMRM, Honolulu; 2009: 2262.
77. Dyke JP, Panicek DM, Healey JH, et al. Osteogenic and Ewing sarcomas: estimation of necrotic fraction = induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology 2003; 228: 271-278.
78. Padhani AR, Dzik-Jurasz A,. Perfusion MR imaging of extracranial tumor angiogenesis. Top Magn Reson Imaging 2004; 15: 41-57.
79. Buckley DL, Drew PJ, Mussurakis S, Monson JR, Horsman A,. Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI. J Magn Reson Imaging 1997; 7: 461-464.
80. Su MY, Cheung YC, Fruehauf JP, et al. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging 2003; 18: 467-477.
81. Knopp MV, Weiss E, Sinn HP, et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 1999; 10: 260-266.
82. Ah-See MW, Padhani AR, Taylor NJ, et al. Evaluation of VEGF expression within breast cancer biopsies & tumour microvasculature assessment by multi-functional dynamic contrast-enhanced MRI. 4th European Breast Cancer Conference (EBCC-4). Hamburg, Germany; 2004.
83. Bhujwalla ZM, Artemov D, Natarajan K, Ackerstaff E, Solaiyappan M,. Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. Neoplasia 2001; 3: 143-153.
84. Matsubayashi R, Matsuo Y, Edakuni G, Satoh T, Tokunaga O, Kudo S,. Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factors. Radiology 2000; 217: 841-848.
85. Tynninen O, Aronen HJ, Ruhala M, et al. MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation. Invest Radiol 1999; 34: 427-434.
86. Lyng H, Vorren AO, Sundfor K, et al. Assessment of tumor oxygenation in human cervical carcinoma by use of dynamic Gd-DTPA-enhanced MR imaging. J Magn Reson Imaging 2001; 14: 750-756.
87. Newbold K, Castellano I, Charles-Edwards E, et al. An exploratory study into the role of dynamic contrast-enhanced magnetic resonance imaging or perfusion computed tomography for detection of intratumoral hypoxia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 74: 29-37.
88. Cooper RA, Carrington BM, Loncaster JA, et al. Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 2000; 57: 53-59.
89. Ferrier MC, Sarin H, Fung SH, et al. Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. Neoplasia 2007; 9: 546-555.
90. Lankester KJ, Taylor JN, Stirling JJ, et al. Dynamic MRI for imaging tumor microvasculature: comparison of susceptibility and relaxivity techniques in pelvic tumors. J Magn Reson Imaging 2007; 25: 796-805.
91. Eby PR, Partridge SC, White SW, et al. Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer. Acad Radiol 2008; 15: 1246-1254.
92. Niermann KJ, Fleischer AC, Huamani J, et al. Measuring tumor perfusion in control and treated murine tumors: correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. J Ultrasound Med 2007; 26: 749-756.
93. Ah-See ML, Makris A, Taylor NJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2008; 14: 6580-6589.
94. Atkin G, Taylor NJ, Daley FM, et al. An investigation of DCE-MRI as a non-invasive measure of angiogenesis in rectal cancer. In: Proc 12th Annual Meeting ISMRM, Kyoto; 2004: 1976.
95. Wilkinson ID, Jellineck DA, Levy D, et al. Dexamethasone and enhancing solitary cerebral mass lesions: alterations in perfusion and blood-tumor barrier kinetics shown by magnetic resonance imaging. Neurosurgery 2006; 58: 640-646; discussion 640-646.
96. Flaherty KT, Rosen MA, Heitjan DF, et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 2008; 7: 496-501.
97. Johansen R, Jensen LR, Rydland J, et al. Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI. J Magn Reson Imaging 2009; 29: 1300-1307.
98. Barentsz JO, Berger-Hartog O, Witjes JA, et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 1998; 207: 791-797.
99. Padhani AR, Hayes C, Assersohn L, et al. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 2006; 239: 361-374.
100. Reddick WE, Taylor JS, Fletcher BD,. Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma. J Magn Reson Imaging 1999; 10: 277-285.
101. Martincich L, Montemurro F, Cirillo S, et al. Role of Magnetic Resonance Imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy. Radiol Med (Torino) 2003; 106: 51-58.
102. Li SP, Makris A, Beresford MJ, et al. Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy. Radiology 2011; 260: 68-78.
103. Bijman MN, van Nieuw Amerongen GP, Laurens N, van Hinsbergh VW, Boven E,. Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton. Mol Cancer Ther 2006; 5: 2348-2357.
104. Bocci G, Nicolaou KC, Kerbel RS,. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002; 62: 6938-6943.
105. de Lussanet QG, Backes WH, Griffioen AW, et al. Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys 2005; 63: 1309-1315.
106. Alonzi R, Padhani AR, Taylor NJ, Stirling JJ, Saunders MI, Hoskin PJ,. Physiological changes within the prostate caused by androgen withdrawal. Clin Oncol (R Coll Radiol) 2007; 19 (3 Suppl): S6.
107. Choi D, Lim HK, Kim SH, et al. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: usefulness of power Doppler US with a microbubble contrast agent in evaluating therapeutic response-preliminary results. Radiology 2000; 217: 558-563.
108. Li W, Brophy DP, Chen Q, Edelman RR, Prasad PV,. Semiquantitative assessment of uterine perfusion using first pass dynamic contrast-enhanced MR imaging for patients treated with uterine fibroid embolization. J Magn Reson Imaging 2000; 12: 1004-1008.
109. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21: 3955-3964.
110. Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008; 26: 4572-4578.
111. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95.
112. Thukral A, Thomasson DM, Chow CK, et al. Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab-initial experience. Radiology 2007; 244: 727-735.
113. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24: 769-777.
114. Jain RK,. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987-989.
115. Tofts PS,. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997; 7: 91-101.
116. Buckley DL,. Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI. Magn Reson Med 2002; 47: 601-606.
117. Galbraith SM, Lodge MA, Taylor NJ, et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed 2002; 15: 132-142.
118. Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003; 21: 2831-2842.
119. Rose CJ, Mills SJ, O'Connor JP, et al. Quantifying spatial heterogeneity in dynamic contrast-enhanced MRI parameter maps. Magn Reson Med 2009; 62: 488-499.
120. Lee KC, Bradley DA, Hussain M, et al. A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia 2007; 9: 1003-1011.